Current status of the Arilvax; yellow fever vaccine

Author: Barrett, Alan DT

Source: Expert Review of Vaccines, 1 August 2004, vol. 3, no. 4, pp. 413-420(8)

Publisher:

Buy & download fulltext article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Abstract:

Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax™ by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.

Keywords: 17D; Arilvax; live attenuated vaccine; yellow fever

Document Type: Miscellaneous

DOI: http://dx.doi.org/10.1586/14760584.3.4.413

Publication date: August 1, 2004

Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page